




# UHPLC Analysis of Trastuzumab on BIOshell™ IgG 1000 Å C4, 2.7 µm



## Conditions:

**column:** BIOshell™ IgG 1000 Å C4, 15 cm x 2.1 mm I.D., 2.7 µm

**mobile phase:** [A] Water (0.1% v/v formic acid, difluoroacetic acid, or trifluoroacetic acid, as indicated)  
[B] 20:80 Water:Acetonitrile (0.1% v/v formic acid, difluoroacetic acid, or trifluoroacetic acid, as indicated)

**gradient:** 35% B to 47.5% B in 12 min

**flow rate:** 0.4 mL/min

**column temp.:** 80 °C

**detector:** UV, 280 nm

**injection:** 2 µL

**sample:** Trastuzumab, varied concentration, 70:30 Water:Acetonitrile

## Description:

Formic acid, difluoroacetic acid, and trifluoroacetic acid are common mobile phase additives. As seen in this analysis of the breast cancer drug trastuzumab, peak shape improves going from formic acid to difluoroacetic acid, and even further improves with trifluoroacetic acid. With this improvement also comes the ability to separate more minor peaks from the monoclonal antibody, as seen in the enlarged insets. The use of trifluoroacetic acid over other additives with the BIOshell™ IgG 1000 Å C4 gives an optimized separation of this monoclonal antibody.

## Materials:

Product Part Number	Description
63289-U	BIOshell™ IgG 1000 Å C4, 15 cm x 2.1 mm I.D., 2.7 µm
270733	Water
34851	Acetonitrile
5.33002	Formic acid
00922	Difluoroacetic acid
302031	Trifluoroacetic acid

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

[SigmaAldrich.com](http://SigmaAldrich.com)

© 2018 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, Supelco, and the vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. Lit. No. PBXXXXXXX XXX

**Supelco**  
Analytical Products